QURE
Uniqure NVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.53B
P/E Ratio
—
EPS
$-3.49
Beta
0.87
52W High
$71.50
52W Low
$8.73
50-Day MA
$19.32
200-Day MA
$26.28
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
27.93
PEG Ratio
0.00
About Uniqure NV
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
Fundamentals
| Revenue (TTM) | $18.09M |
| Gross Profit (TTM) | $-113.63M |
| EBITDA | $-174.86M |
| Operating Margin | -1321.00% |
| Return on Equity | -228.20% |
| Return on Assets | -17.00% |
| Revenue/Share (TTM) | $0.30 |
| Book Value | $3.19 |
| Price-to-Book | 10.22 |
| Price-to-Sales (TTM) | 84.32 |
| EV/Revenue | 55.4 |
| EV/EBITDA | 1.40 |
| Quarterly Earnings Growth (YoY) | -18.20% |
| Quarterly Revenue Growth (YoY) | 127.30% |
| Shares Outstanding | $63.07M |
| Float | $53.71M |
| % Insiders | 5.53% |
| % Institutions | 96.02% |
Historical Volatility
HV 10-Day
56.39%
HV 20-Day
103.90%
HV 30-Day
97.91%
HV 60-Day
149.79%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($39.05 target)
1
Strong Buy8
Buy4
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026